2019 Bioelectronic Medicine Forum

Millennium Broadway, New York, NY, April 4,2019

Keynote Speaker

Sue Siegel, Chief Innovation Officer, GE and CEO, Business Innovations

Sue Siegel is GE’s Chief Innovation Officer and CEO of Business Innovations, leading the development and acceleration of innovation across the company. An innovator at heart, she is a seasoned executive focused on uncovering new and unconventional paths to growth. She has 30+ years of corporate, entrepreneurial, and venture capital experience, all geared at one thing: turning untapped potential into real value. In this role, Sue leads Business Innovations, a multimodal innovation engine focused on accelerating promising start-ups in GE Ventures, creating and launching new companies, licensing GE’s intellectual property, developing new markets, and nurturing innovative ideas into scalable initiatives both inside and outside of GE. To date, Sue and her team have led the creation and launch of seven new companies including Drawbridge Health, Avitas Systems, Vineti and Evidation Health, funded and accelerated growth for 100+ companies and led the creation of a novel licensing model for GE’s library of patents – connecting technology and ideas to create new avenues to growth. Previously, as a Silicon Valley-based venture capitalist at MDV, Sue led investments and served as board member for companies in personalized medicine, digital health, and life sciences. Prior to that, Sue served as president and board member of Affymetrix, where she led the company’s transformation from a pre-revenue startup to a global, multi-billion dollar market cap genomics leader. She also led strategy, technology development, licensing, manufacturing, and new market creation and development at leading organizations including Bio-Rad, DuPont, and Amersham. Sue has been recognized in Fortune as one of “34 Leaders Who Are Changing Health Care” and as one of “The 100 Most Influential Women in Silicon Valley” by Silicon Valley Business Journal. She is an Aspen Institute Crown Fellow and was featured as a “Multiplier” in the bestselling book: Multipliers: How the Best Leaders Make Everyone Smarter. Sue holds an M.S. from Boston University School of Medicine and a B.S. from the University of Puerto Rico. She lives in Silicon Valley with her husband and has two sons. She is an avid hiker and loves to spend time on the scenic trails of Northern California.

Conference Moderators

James Cavuoto, Editor and Publisher, Neurotech Reports

James Cavuoto is editor and publisher of Neurotech Business Report and the founder of Neurotech Reports. He is the lead author of "The Market for Neurotechnology," and "The Market for Bioelectronic Medicine," two market research reports published by Neurotech Reports. Cavuoto was the founder of Micro Publishing Press, Inc., a publishing company that helped pioneer the market for electronic publishing, digital imaging, and computer graphics. He holds a degree in biomedical engineering from Case Western Reserve University, where he studied under pioneers in the field of functional electrical stimulation. He has also studied human factors engineering at University of Southern California in Los Angeles. Cavuoto spent three years as a member of the technical staff at Hughes Aircraft Company in Los Angeles, where he worked on simulation, training, and publication products produced for the U.S. Department of Defense. Cavuoto was an adjunct professor at Rochester Institute of Technology and the author of eight books on computer graphics, electronic publishing, and digital imaging. He is a member of the IEEE Engineering in Medicine and Biology Society. He has authored a chapter in the textbook Neuromodulation (Elsevier, 2009), as well as articles in Neuromodulation, Journal of Neural Engineering, Medical Device Daily, IEEE Spectrum, MX magazine, and the International Journal of Medical Marketing. He is coauthor, with Jennifer French, of Bionic Pioneers: Brave Neurotech Users Blaze the Trail to New Therapies (Neurotech Press, 2014).

Imran Eba, Partner, Action Potential Venture Capital

Imran is a partner at Action Potential Venture Capital in Cambridge, MA and invests in companies that are pioneering bioelectronic medicines and technologies. He represents Action Potential as a Board Member or Observer on the boards of Axon Therapies and SetPoint Medical. Before joining Action Potential, Imran was in the Worldwide Business Development group of GlaxoSmithKline working in a variety of business development and investing roles. Most recently, Imran led the establishment of and headed up the Investment Management practice at GlaxoSmithKline. The group was tasked with accessing technology and innovation external to GSK by making and managing investments in life science venture capital funds as limited partners and direct investments in biotechs made as part of GSK’s R&D collaborations. During his tenure the group led GSK’s commitments in excess of $200 million in a number of venture capital groups as well as participated in a number of biotech IPOs. Imran received his bachelor’s degree in finance from Concordia University in Montreal and has trained as a Canadian Chartered Accountant.

Jennifer French, Senior Editor and Associate Publisher, Neurotech Reports

Jennifer French is senior editor and associate publisher of Neurotech Reports. She is the founder of Neurotech Network, a nonprofit organization founded in Florida in 2003. Jennifer acquired her C6-7 incomplete spinal cord injury in 1998. Prior to her injury, she was recreationally active with such sports as canoeing, snowboarding/skiing, sailing, fly fishing, biking. After her injury, she still participates in all those activities. She is an active user of an FES system. Now residing in Tampa, FL, Jen is active in the community accessible sailing program, Sailing Alternatives as well as the national US Sailing, Sailors with Special Needs. French has helped launch successful divisions is such organizations as Bombardier Capital and PC Connection, Inc. With an MBA specializing in marketing & strategy, she works with for-profit and not-for-profit organizations, large and small, emerge into new markets, profile target customers and create and build systems to support sales efforts. She is the author of On My Feet Again (Neurotech Press, 2013), her personal story of rehabilitation using neurotechnology.

Jeremy Koff, Senior Contributing Editor, Neurotech Reports

Mr. Koff is senior contributing editor for Neurotech Reports and president of Colibri Partners Inc., a strategic and marketing consulting firm with a primary focus in the medical device sector. The company offers services related to market and risk analysis, clinical and technology assessments, business plan development, business/financial modeling, and market research. Mr. Koff has nearly 20 years of global experience in the medical device industry with companies including Advanced Bionics Corp., Boston Scientific, MiniMed Inc., Bioness Inc, and many others. His business plans have attracted tens of millions in start-up capital. Mr. Koff holds a Bachelor's degree in biology from Middlebury College, a Masters of Public Affairs from Indiana University, and an MBA from UCLA. He is an active classically-trained musician, supporter of the arts, and is a board member of the Fender Music Foundation.

Margot Puerta, Contributing Editor, Neurotech Reports

Margot Puerta is a contributing editor to Neurotech Reports and a coauthor of Neurotech Reports' new market study, "The Market for Bioelectronic Medicine." She was previously the Executive Editor of two journals published by the Feinstein Institute for Medical Research: Molecular Medicine and Bioelectronic Medicine. There, she was  responsible for strategically guiding the development of the journals, including web and multimedia content. Prior to assuming these roles, Margot worked as the laboratory manager for the Laboratory of Biomedical Science at the Feinstein Institute co-authoring papers describing neural control of the immune system. Margot holds a B.S. in biology from Fairfield University, an M.S. in biology from Hofstra University and an M.B.A. in finance from the Frank G. Zarb School of Business, Hofstra University.

Panelists and Presenters

Evan Norton, Divisional Vice President, Abbott Ventures

Evan Norton joined Abbott Ventures in 2010. Prior to Abbott Ventures, he was a Principal with ONSET Ventures focused on medical technology investing. He has a diverse background of experience in medical technology including the orthopedics, diabetes, and ear, nose, and throat markets. Evan also worked at Acclarent, Inc. and Johnson & Johnson’s diabetes company, LifeScan Inc. In addition to his medical device experience, Evan worked for Compaq Computer Corporation’s Strategic Investments group. Evan holds an MBA degree from the J.L. Kellogg Graduate School of Management and a BBA in Finance from Texas A&M University, cum laude.

Jeffrey Erb, Senior Director of Business Development, Medtronic

Jeffrey Erb is the Director of Business Development, Alliances and IP Portfolio Management for Medtronic Neuromodulation. Mr. Erb has worked for Medtronic since 2002 in a variety of roles including Corporate Development, Strategic Pricing, Strategic Planning and Marketing. He also serves as the Co-Collaboration Manager and CFO of MG Biotherapeutics, a joint venture in Cardiac Cell Therapy with Genzyme. Prior to working for Medtronic, Mr. Erb held various finance positions for Lockheed Martin. He earned an MBA degree from the University of Michigan and a bachelors degree from the University of Pittsburgh in economics and business.

Eric Van Gieson, Ph.D., Program Manager, DARPA Biological Technologies Office

Dr. Eric Van Gieson joined DARPA as a Program Manager in August 2017 with the goal of using host-based methods to mitigate the impacts of emerging disease threats. He intends to explore epigenetic and real-time monitoring approaches that can dynamically guide healthcare decisions and therapy, and new methods of increasing patient survival in austere environments using intelligent systems partnered with local care providers. Throughout his career, Dr. Van Gieson has worked with private and interagency government partners to build diagnostic and healthcare solutions. For example, he leveraged those partnerships to develop a novel patient transport system known as the Containerized BioContainment System, a platform that received an “R&D 100” award and is currently in use by the Departments of State and Health and Human Services. He also created a university-based drug development pipeline to accelerate development of therapeutic products for guarding against WMD and emerging disease threats. His work has led to technology that links home-use and point-of-care diagnostics with health surveillance capabilities, especially in resource-limited environments, with the goal of stopping epidemics before they emerge. Dr. Van Gieson has also led technology development and evaluation efforts in diagnostics for the Department of Defense, and has supported major diagnostics acquisition and science and technology programs. Dr. Van Gieson received his Ph.D. in Biomedical Engineering and a Bachelor of Science degree in Chemical Engineering from the University of Virginia. He has published on topics ranging from genomic analysis to autonomous systems.

Adam Fine, General Manager and CEO, Windham Venture Partners

Adam Fine is a co-founder and CEO of Windham Venture Partners. Adam is currently Director at Coravin, GlySens, CuraSeal and HelpAround, board observer to SpineView, MC10, Holaira, and VytronUS. Adam is a mentor in Blueprint Health, a healthcare IT accelerator in New York City. Prior to Windham, Adam was VP & GM at I-many, Inc., an enterprise software company. Prior to joining I-many, Adam was a New Business Development Analyst at Cordis Corp., a Johnson & Johnson company focused on interventional vascular devices such as stents. In that capacity, Adam worked on a range of licenses, acquisitions, divestments, as well as strategic investments with Johnson & Johnson Development Corporation (JJDC), J&J’s strategic venture arm. Prior to J&J, Adam was a research analyst at Coopers & Lybrand’s Integrated Healthcare Consulting practice. Adam received his BA and graduated cum laude with distinction from Boston University and received his MBA from New York University.

Marom Bikson, Ph.D., Professor of Biomedical Engineering, City College of New York

Marom Bikson is a Cattell Professor of Biomedical Engineering at The City College of New York of the City University of New York and co-Director of the Neural Engineering Group at the New York Center for Biomedical Engineering. The translational R&D activity of his group spans pre-clinical studies, computational models, device design and fabrication, regulatory activities, and clinical trials. Technologies developed by his group are in clinical trials in over 100 medical centers and include neuromodulation interventions for neuropsychiatric disorders, intra- and post-operative sensors, patient compliance tools, and surgeon training simulators. Dr. Bikson has published over 200 papers and book chapters and is inventor on over 30 patent applications. He is known for his work on brain targeting with electrical stimulation, cellular physiology of electric effects, and electrical safety. Dr. Bikson co-invented High-Definition transcranial Direct Current Stimulation, the first noninvasive, targeted, and low-intensity neuromodulation technology. Dr. Bikson consults for medical technology companies and regulatory agencies on the design, validation, and certification of medical instrumentation. Prior to becoming faculty at CUNY, Dr. Bikson was a research fellow at the University of Birmingham Medical School, U.K. and a Research Associate at Sontra Medical LLC, in Cambridge, Massachuesetts. Dr. Bikson received his Ph.D. in Biomedical Engineering from Case Western Reserve University, in Cleveland, OH and a B.S. in Biomedical Engineering from Johns Hopkins University, Baltimore, MD.

Samuel Hamner, Ph.D., Director of Product Innovation, Cala Health

Samuel Hamner is director of product innovation at Cala Health. He was part of the core team that designed and developed the first-ever noninvasive, targeted nerve stimulator for the relief of essential tremor to receive FDA clearance. Cala is a medical technology company developing wearable neuromodulation therapies that spun out of the Stanford BioDesign program in 2014. Prior to Cala, Sam was a designer at D-Rev, a non-profit that delivers medical technologies for under-served populations. He holds a Ph.D. in Biomechanics from Stanford University and has authored more than 30 patents and peer-reviewed publications. 

Shai Gozani, M.D., Ph.D., President and CEO, NeuroMetrix, Inc.

Shai Gozani founded NeuroMetrix, Inc. in 1996 as a spin-off from the Massachusetts Institute of Technology. He currently serves as chairman of the board of directors and president and CEO. Shai has led the company from a venture capital backed start-up, through an initial public offering on Nasdaq, through development of a successful diagnostics business, and presently into the wearable technology sector. More than 2.5 million patients have benefited from the company’s technology over the past 17 years. Shai has published more than 30 peer-reviewed scientific articles and has been awarded 25 U.S. and international patents. He holds a B.A. degree in computer science, an M.S. degree in electrical engineering & computer science (biomedical engineering focus) and a Ph.D. in neurobiology, from the University of California, Berkeley. Shai also received an M.D. from Harvard Medical School and the Harvard-MIT Division of Health Sciences and Technology at M.I.T.

Jacob Zabara, Ph.D., Founder, Jacob Zabara Family Foundation

Dr. Zabara has developed a new Brain ElectroDynamic Modulation (BEAM) technology based on his work with vagus nerve stimulation and LivaNova's NeuroCybernetic Prothesis, whch he invented at the launch of Cyberonics Inc. The Zabara Foundation is pursuing partnerships to fund therapies and clinical trials based on BEAM and related patents. BEAM is a result of the observations in animal and clinical research in VNS and neuromodulation, but takes neuromodulation in a new direction. Dr. Zabara was on the faculty at Temple University until 1996 with visiting appointments at Stanford University Hadassah Medical School and NASA-Ames. His education was at Johns Hopkins University in Physics and Biophysics, and the University of Pennsylvania in Physiology, where he was a fellow in the Institute of Neurological Sciences. His initial positions were at Dartmouth Medical School and the University of Pennsylvania.

Corey Hunter, M.D., Assistant Clinical Professor, Mt. Sinai Hospital

Corey Hunter is a pain management specialist at the Ainsworth Institute of Pain Management and a professor at Mount Sinai Health System. He completed his residency in Physical Medicine and Rehabilitation at NYU Langone Medical Center and a fellowship in Pain Medicine at Weill Cornell Medical College. Dr. Hunter is actively engaged in clinical research focusing on spinal cord stimulation, RF ablation and stem cell therapy. He has numerous publications to his credit, including a number of contributions to textbooks on treating pain and several articles published in peer-reviewed journals. Dr. Hunter is an active member of professional organizations including the North American Neuromodulation Society, International Neuromodulation Society, American Society of Interventional Pain Physicians, and American Society of Regional Anesthesia. Dr. Hunter is considered to be a rising star and key opinion leader in the field of pain management. He lectures all over the country on the latest breakthroughs and has numerous publications to his credit, including a number of contributions to textbooks on treating pain and several articles published in peer-reviewed journals. In addition, he is a consultant and instructor for several companies who research and develop treatments for chronic pain including Abbott. Currently, Dr. Hunter maintains privileges at Lenox Hill Hospital and Beth Israel Medical Center. He is licensed in New York, New Jersey, and Florida.

Peter Staats, M.D., Founder and Chief Medical Officer, electroCore Medical LLC

Dr. Staats, a co-founder of electroCore, has been on the board of electroCore since its inception. He was the founder of the Division of Pain Medicine at Johns Hopkins University, where he was the director for 10 years. Dr. Staats is internationally recognized for his work in developing and implementing minimally invasive procedures for chronic pain, and his patents have led to the use of novel pharmacologic agents (Qutenza patch). Dr. Staats received his medical degree from the University of Michigan Medical School in Ann Arbor and completed his residency and fellowship training at the Johns Hopkins University School of Medicine. He is a past President of the North American Neuromodulation Society, American Society of Interventional Pain Physicians, New Jersey Society of Interventional Pain Physicians, and the Southern Pain Society. He is currently Chairman of the Board of Examination of the World Institute of Pain and continues to serve as Chief Medical Officer for National Spine and Pain Centers, the largest pain practice in the United States. Dr. Staats has written or co-edited 10 books and over 300 articles, abstracts, monographs, and book chapters on pain medicine in publications that include the Journal of the American Medicine Association, Pain, Anesthesiology, and the Journal of Clinical Oncology.

Victor Pikov, Ph.D., CEO, Medipace, Inc.

Victor Pikov is CEO of a recently established Pasadena-based company, MediPace Inc., which is focused on the development of implantable stimulation-based therapies for the GI tract. Prior to that, for the past three years he worked at Galvani Bioelectronics and GSK Bioelectronics division, where he oversaw the development and validation of implantable pulse generators and stimulation leads (nerve cuffs and percutaneous electrodes) for several clinical applications. Prior to Galvani Bioelectronics, while at the Huntington Medical Research Institutes (2002-2015), Victor evaluated PNS and CNS neural interfaces in various models of chronic diseases, such as infertility, bladder paralysis, bladder spasticity/hyperreflexia, hearing and vision loss, tinnitus, obstructive sleep apnea, and obesity. His Ph.D. work at Georgetown University (1995-2000) was on the spinal control of bladder voiding and postdoctoral work at the California Institute of Technology (2000-2002) was on optogenetic viral vectors for neuronal stimulation. Victor holds several patent applications for noninvasive glucose measurement in the skin, neuromodulation for polycystic ovarian syndrome, and a microfluidic nerve cuff interface.

Elliot Krames, M.D., Former President, International Neuromodulation Society

Elliot Krames is a nationally and internationally known “thought leader” in the field of pain medicine and neuromodulation. He graduated from medical school at the University of Maryland and completed his residency in anesthesiology and his fellowship in obstetrical anesthesia at the University of California, San Francisco. Dr. Krames is board certified in anesthesiology and sub-certified in pain management through the American Board of Anesthesiology. He is certified in pain medicine through the American Board of Pain Medicine. The first cancer pain clinic at Mount Zion Hospital was established by Dr. Krames in 1982. He established the Pacific Pain Treatment Center in 1987. Dr. Krames was previously president of the International Neuromodulation Society and has served on the Boards of The North American Neuromodulation Society, The National Pain Foundation, The World Institute of Pain, The American Academy of Pain Medicine, and The American Board of Pain Medicine. Dr. Krames was Editor-in-Chief for 13 years of Neuromodulation, Journal of the International Neuromodulation Society. Dr. Krames has co-authored two previous books and was editor of a two volume textbook, Neuromodulation.

Kip Ludwig, Ph.D., Associate Professor, University of Wisconsin-Madison

Dr. Ludwig leads the Bioelectronic Medicines Laboratory at the University of Wisconsin. The primary focus of his lab is developing next-generation neuromodulation therapies that use minimally invasive strategies to ‘wiretap’ the nervous system to treat circuit dysfunction and deliver biomolecules to target areas with unprecedented precision. Prior to Wisconsin Dr. Ludwig served as the Program Director for Neural Engineering at the National Institutes of Health. He co-led the Translational Devices Program at NINDS, led the NIH BRAIN Initiative programs to catalyze implantable academic and clinical devices to stimulate and/or record from the central nervous system, and led a trans-NIH planning team in developing the ~250 million dollar S.P.A.R.C. Program to stimulate advances in neuromodulation therapies for organ systems. Dr. Ludwig also worked in industry as a research scientist, where his team conceived, developed and demonstrated the chronic efficacy of a next-generation neural stimulation electrode for reducing blood pressure in both pre-clinical studies and clinical trials. Through his industry work he oversaw Good Laboratory Practice and non-GLP studies enabling clinical trials in Europe and the U.S., as well as participated in the protocol development and execution of those trials, leading to approval for sale in seven countries and a U.S. pivotal trial.

Jeff Kramer, Ph.D., Vice President, Research and Technology, Medtronic

Jeff Kramer is vice president of research and technology for Medtronic's Restorative Therapies Group. He was previously vice president of clinical research for Kernel. Prior to that, he was vice president and fellow for neuromodulation research and development at Abbott (formerly St Jude Medical). At Abbott, Jeff was responsible for leading and conducting early phase research in new therapy development and discovery, as well as research focusing on product improvements across multiple therapeutic areas including chronic pain (intraspinal stimulation) and movement disorders (brain stimulation). Jeff holds a Ph.D. in neuroscience from the University of Illinois and is published extensively in the field of both autonomic and neuromodulation fields. Prior to joining St Jude Medical, he held the position of chief scientific officer at Spinal Modulation, where he developed and led the scientific and clinical research efforts from early phase through regulatory approvals and company acquisition.

Entrepreneur Presenters

Daniel Powell, CEO, Spark Biomedical Inc.

Daniel Powell has more than 20 years experience developing and selling technology-based products and has served in leadership roles in upstream and downstream marketing, business development, strategic planning, and program management. Powell launched more than 18 medical device products during his career at St. Jude Medical (now Abbott) and Cyberonics (now LivaNova). He has a wide range of experience in the the neurological disorders space including movement disorders, psychiatric disorders, and epilepsy. Additionally, Powell has in-depth experience in interventional neuromodulation technology, both implanted and external, as well as other active implantable medical technology, bio monitoring, and disease management systems. Powell now leads his own startup, Spark Biomedical, and acts as an advisor for other startups in the industry.

Jennifer Ernst, Co-founder and CEO, Tivic Health Systems Inc.

Jennifer Ernst is CEO at Tivic Health Systems Inc. in Menlo Park, CA. Her career in technology has been characterized by driving transformational technology to market. She began her career at Xerox PARC in Palo Alto, one of the world’s leading research laboratories, focused on getting technology out of the lab and into the market. She held varying roles in strategic business development, marketing, and sales. Ernst holds an MBA from Santa Clara University, graduating with honors. For the past 15 years, Ernst has dedicated herself to identifying and building global businesses out of cutting-edge technologies. Prior to founding Tivic Health, she served as executive vice president of sales and marketing, chief strategy officer, and CEO of the U.S. subsidiary of Thin Film Electronics. Of note, she launched early electronic labels which led to the company winning the Wall Street Innovation Award and the World Technology Award. In addition, as part of the company’s executive management, Ernst transformed the company from an eight-person R&D company to a recognized leader in printed electronics with a peak market cap of $480 million in less than five years.

Attila Borbath, Co-founder and CEO, Synergia Medical

Attila Borbath’s M.Sc. in Business Administration and Engineering from the UCLouvain followed by the CEMS Master’s in International Management naturally brought him to pave his professional way in a technological start-up in the finance sector for 10 years. In parallel, he obtained his airline transport pilot license. He was then convinced by the idea of of joining an innovative startup where he had the role of vice president of sales and marketing. In 2013, he moved to Synergia Medical, which he co-founded. Well traveled, multilingual, and energetic, Attila has developed remarkable management, entrepreneurial, marketing, and business development skills.

Don Deyo, CEO, FemPulse LLC

Don Deyo is the CEO of FemPulse LLC. Prior to this, Mr. Deyo served in executive leadership roles at Medtronic, Inc., the world’s largest medical device company. He also founded the executive consultancy MedTech Execs, which provides strategic and operational services to medical device and pharmaceutical companies through a global network of experienced executives. While with Medtronic, Mr. Deyo was Vice President of Research & Development for Neuromodulation, Vice President of Product Development & Technology for Cardiac Rhythm Management and Vice President and General Manager for Medtronic Paceart. Mr. Deyo holds advanced degrees in engineering and business administration.

David Hochman, Chairman and CEO, Orchestra BioMed

Mr. Hochman has more than 20 years of venture capital and investment banking experience. Since 2007, he has been Managing Partner of Orchestra Medical Ventures, LLC, an investment firm that employs a strategy to create, build, and invest in medical technology companies intended to generate substantial clinical value. Mr. Hochman served as the president of Accelerated Technologies, Inc., a medical device accelerator company managed by Orchestra Medical Ventures. He was a co-founder of Caliber and has been on the board of Caliber since 2009 and serves as its chairman. He was a co-founder of BackBeat and has served as its president and a member of its board since inception in 2010. He is also chairman of the board for Motus GI and a director of FreeHold Surgical, Inc., both of which are Orchestra Medical Ventures portfolio companies. Prior to joining Orchestra Medical Ventures, Mr. Hochman was CEO of Spencer Trask Edison Partners, LLC, an investment partnership focused on early stage healthcare companies. From 1999 to 2006, Mr. Hochman was a board advisor of Health Dialog Services Corp., a leader in collaborative healthcare management that was acquired in 2008 by the British United Provident Association for $750 million. He currently serves on the board of two non-profit organizations: the Citizens Committee for New York City and the Mollie Parnis Livingston Foundation (a family foundation for which he is also President). He has a B.A. degree with honors from the University of Michigan.

Nader Yaghoubi, M.D., Ph.D., President and CEO, PathMaker Neurosystems Inc.

Dr. Yaghoubi has over 20 years of experience in the creation, operations, and financing of life science companies. Before starting PathMaker Neurosystems, he established, as president and Founding CEO, Symbiotix Biotherapies, a pioneering microbiome company developing novel molecular therapeutics based on the human microbiome. Prior to that, he was the first employee at Selecta Biosciences and BIND Therapeutics, where he worked with the founders to launch the companies and establish operations and corporate development. Previously, he was at Zero Stage Capital, a venture capital firm where he was responsible for investing in the life sciences sector, and earlier completed an internship at Advent International. Prior to this, he was a Health Care Entrepreneurship Fellow at Boston University, where he worked with scientists and physicians to develop new businesses in the healthcare and life science sector. Before his fellowship, he was a surgical resident in the Department of Surgery at Lenox Hill Hospital in New York. Dr. Yaghoubi received an M.D. and Ph.D. in Molecular Pharmacology from the combined degree program at Boston University School of Medicine. His doctorate work on the development of high-throughput automated electrophysiological systems resulted in five issued U.S. patents, received one of the University’s highest awards for dissertational research, and was the basis of a venture-backed biotechnology company focused on neuroscience. He is extensively involved in mentoring young companies, and has served/serves as a mentor, advisor and reviewer with MBC’s MassCONNECT program, Mass Life Sciences Center programs, Springboard Venture Capital Forum, and numerous university business plan competitions.

Douglas Adams, President and CEO, Qura Inc.

Douglas Adams currently serves as president and CEO of Qura. He has more than 20 years of global experience as a medical device industry CEO. Previously he was the founder, president, and CEO of a glaucoma device company. He was responsible for recruiting a qualified management team and growing the company’s employee base. He assisted in attracting $35,000,0000 in capital through venture capital firms, private equity firms and other institutional investors to commercialize its lead product - the Gold Shunt. Mr. Adams is actively engaged in ongoing technology development, market development, and regulatory and clinical strategies and tactics for Qura. He works closely with key physician luminaries to participate in the company’s product development and clinical trials. Mr. Adams has commercialized transformational Class II and Class III device concepts into global markets. As CEO he interacts extensively with board members, physicians, engineers, regulatory, clinical, marketing professionals, investors, industry analysts, and government agencies including the FDA. 

Ana Maiques, CEO, Neuroelectrics

Ana Maiques is the CEO of Neuroelectrics, a company aiming to change the way we interact with the brain; developing innovative technologies to monitor and stimulate the brain. She was nominated by IESE as one of the most influential entrepreneurs under 40 in Spain in 2010; she was the only woman on that list. She received the EU Prize for Women Innovators from the European Commission EC in 2014. Also in 2014, she was an award recipient of the International Women’s Entrepreneurial Challenge. In 2015 and 2016, she was named one of most inspiring women on the Inspiring Fifty list in Europe of women technological leaders and innovators. As a company, Neuroelectrics received the Best Start-up in Health Award in 2015 by Wired UK magazine and in 2016 was recognized as one of the “Best Entrepreneurial Companies in America” by Entrepreneur Magazine’s Entrepreneur 360 List. Ana continues to break the barriers for women and entrepreneurs bringing together science and technology in an impactful way.

Shelley Fried, Ph.D., Associate Professor of Neurosurgery,
Harvard Medical School/Massachusetts General Hospital

Shelley Fried is the Director of the Neural Prosthetic Research Laboratory at Massachusetts General Hospital and an Associate Professor in the Department of Neurosurgery at Harvard Medical School. His lab develops novel technology to more effectively stimulate the CNS. They are currently pioneering a system that uses tiny, implantable coils to magnetically stimulate the cortex. The system offers significant advantages over conventional micro-electrodes and is currently being developed into a cortical visual prosthesis. Dr. Fried has a Ph.D. in Vision Science from UC Berkeley where he studied the neurobiology of the visual system. He did postdoctoral training at both UC Berkeley and at the Massachusetts General Hospital in Boston studying artificial stimulation of the CNS. Prior to obtaining his Ph.D., he worked in biomedical industry for about 12 years, starting as a design engineer for Pall Biomedical Products and ultimately, as the director of engineering for Vital Signs, Inc.

Gaurav Sharma, Ph.D., Technical Leader in Neuromodulation, Battelle

Gaurav Sharma’s work has helped a paralyzed patient regain control of his hand and enabled delivery of drugs across the blood-brain barrier. As the Lead Investigator and Senior Research Scientist on the Battelle Medical Devices and Neuromodulation team, he is applying advanced engineering to overcome problems in the human body and brain. Since joining Battelle in 2011, Gaurav has served as the technical lead or lead investigator on a number of cutting-edge projects involving peripheral nerve stimulation, spinal cord stimulation, and brain-computer interfaces. He was also the lead investigator for the Blood-Brain Barrier engineering program, a Defense Threat Reduction Agency-funded project aimed at developing nanotechnology-based strategies for delivery of drugs to the brain. Gaurav’s work is informed by his background in biomedical and mechanical engineering. He holds a Ph.D. in mechanical engineering from Northeastern University, an M.S. in mechanical and aerospace engineering from Rutgers University and a B.S. in mechanical engineering from the National Institute of Technology in Surathkal, India. His doctoral work was focused on the development of protein-based bio-nano sensors. In his postdoctoral work at the Sanford-Burnham Medical Research Institute, he expanded on this work to develop nanotechnology-based strategies for engineering the tumor microenvironment as a therapeutic strategy against breast cancer. His background in engineering, advanced materials, and biology has given him a cross-disciplinary perspective that has been invaluable in solving difficult challenges in medical device design.

Michael Jenkins, Ph.D., Investigator, Cleveland FES Center

Michael Jenkins is an investigator at the Cleveland FES Center and an assistant professor of biomedical engineering and pediatrics at Case Western Reserve University. He received his Ph.D. in biomedical engineering from Case Western Reserve University in 2008. Jenkins' lab is currently investigating the mechanisms of action and determining whether infrared neuromodulation has the potential to map/decode autonomic circuitry, and as a clinical device. A congenital heart defect is an evident structural anomaly of the heart or thoracic great vessels with real or potential functional impact. Among all birth defects, CHDs are one of the most common and devastating, afflicting 32,000 babies born in the U.S. each year and over 1 million Americans alive today. His group develops new technology to study structure/function relationships in the developing heart.

Thomas Oxley, M.D., Ph.D., Associate Professor, University of Melbourne and CEO, Synchron Inc.

Dr. Oxley is the founder and CEO of Synchron, and led the original team that created the Stentrode device at the University of Melbourne. He now leads the company and also holds the position of neurointerventionalist in the department of neurosurgery at Mount Sinai Health System, after having completed an endovascular neurosurgery fellowship at Mount Sinai Hospital under Dr. J Mocco and Dr. Alejandro Berenstein. Dr. Oxley also completed residencies in both internal medicine and neurology, as well as a stroke fellowship, and holds a Ph.D. from the University of Melbourne in neural engineering, which includes advanced MRI imaging analysis, hardware device (stent) development, and electrophysiological signal processing. His work has been published in major journals including Nature Biotechnologyand New England Journal of Medicine. Dr. Oxley established the Vascular Bionics laboratory at the University of Melbourne, which received substantial funding from DARPA, and is the founder of three start-up companies: SmartStent, VascuLab, and Synchron.

      

©2019 Neurotech Reports. All rights reserved.